Clinical Trial Update: Clinical Trial of Recombinant Pneumococcal Protein Vaccine [Phase 1]

View source ↗

Summary

Phase 1 trial of a recombinant pneumococcal protein vaccine by CanSino Biologics Inc. has completed. The study targeted pneumonia and respiratory tract infectio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia
• Respiratory Tract Infections

Drugs mentioned

• Recombinant Pneococcal Protein Vaccine

Snippet

Sponsor: CanSino Biologics Inc. | Conditions: Pneumonia, Respiratory Tract Diseases | Phase 1 | Status: COMPLETED